Market Overview - The market experienced a decline with all three major indices closing lower: Shanghai Composite Index down 0.51%, Shenzhen Component Index down 0.78%, and ChiNext Index down 1.12% [1] Sector Performance - Coal, wind power equipment, and traditional Chinese medicine sectors showed strong gains, while energy metals, internet services, and software development sectors faced significant declines [1] - Main capital inflows were observed in small metals, optical electronics, and non-ferrous metals industries [1] ETF Performance - Related ETFs such as those in non-ferrous metals, electricity, and traditional Chinese medicine performed well, likely influenced by relevant news [1] Federal Reserve Insights - China Galaxy Securities noted that market expectations for a Federal Reserve rate cut in December have exceeded 80%, leading to a rebound in gold prices and a new high for silver prices [1] - The ongoing rate cut cycle and potential shift from balance sheet reduction to expansion may continue to support rising prices for gold and silver [1] Resource Sector Outlook - CITIC Construction indicated that conditions are accumulating for a strong performance in resource products, which may become a new main investment theme in A-shares following technology [1] - The competition for key resources amid external geopolitical tensions is expected to be a significant factor driving the strength of resource products [1] New Energy and Grid Investment - Zhongyou Securities highlighted that the demand for new energy consumption is surging under the "dual carbon" goals, leading to a rapid growth cycle in grid investment [2] - The urgency for smart grid upgrades, along with infrastructure needs for ultra-high voltage channels and distribution network improvements, is driving this investment trend [2] Traditional Chinese Medicine Pricing Regulation - The launch of the drug price registration system in China is part of a broader initiative to regulate the prices of traditional Chinese medicine [3] - Multiple regions, including Heilongjiang, Anhui, and others, are actively implementing price governance measures targeting high-priced traditional Chinese medicines [3] - The goal is to establish a unified, open, and competitively ordered drug market across the country [3]

Core Viewpoint - The A-share market continues to decline, with major indices experiencing losses, while the traditional Chinese medicine (TCM) ETFs show resilience and growth amid a recovering market sentiment in the TCM sector [1][2]. Market Performance - The Shanghai Composite Index fell by 0.51% to 3878 points, the Shenzhen Component Index dropped by 0.78%, and the ChiNext Index decreased by 1.12% [1]. - The total market turnover reached 1.68 trillion yuan, an increase of 763 billion yuan compared to the previous trading day, with over 3800 stocks declining [1]. TCM ETFs - TCM ETFs, including the TCM ETF, TCM ETF Huatai-PB, and TCM 50 ETF, experienced gains, with respective increases of 0.92%, 0.90%, and 0.81% [2]. - The TCM ETF tracks the CSI Traditional Chinese Medicine Index, with key stocks including Yunnan Baiyao, Pien Tze Huang, and Tong Ren Tang [1][2]. TCM Market Trends - The TCM market is showing signs of recovery, with increased market activity and positive investment sentiment [2]. - The TCM sector benefits from both pharmaceutical and consumer attributes, with a high dividend yield of 2.69% over the past 12 months, placing it in the 90.91% historical percentile since its inception [2]. Price Governance in TCM - Multiple regions in China have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive drug market [3][4]. - The focus is on high-priced TCM products with significant clinical usage, particularly those sold primarily in the outpatient market [4]. Industry Dynamics - The ongoing price governance and centralized procurement are expected to lead to price convergence between hospital and outpatient markets, reshaping competitive factors in the industry [4]. - Companies with unique products, strong clinical value, and effective cost control are likely to gain competitive advantages [4]. Investment Themes - Three main investment themes are identified: 1. Price governance, focusing on price reductions and market share for competitive products [5]. 2. Consumption recovery, driven by macroeconomic improvement and aging population, benefiting TCM sales [6]. 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [6]. Recommended Investment Targets - Companies with strong R&D capabilities, unique products, and those less affected by centralized procurement are recommended for investment [6]. - Emphasis is placed on TCM brands with strong market presence and those benefiting from state-owned enterprise reforms [6].

Group 1 - Chinese medicine concept stocks are experiencing a downturn, with notable declines including Guangdong Wannianqing down over 13%, Zhongsheng Pharmaceutical hitting the daily limit down, Yiling Pharmaceutical down over 2%, and Pian Zai Huang down over 1% [1] - Related ETFs for Chinese medicine have also dropped by over 1% [1] Group 2 - Several brokerages express optimism regarding the recovery of consumption in the context of macroeconomic improvement and domestic demand stimulation, which is expected to boost sales of consumer-oriented Chinese medicine [2] - The aging population and increased health awareness among residents are identified as significant long-term drivers for consumer-oriented Chinese medicine [2] - The characteristics of the Chinese medicine industry, including its long industrial chain and the "prevention-treatment-nurturing" model, are anticipated to be more fully realized [2] - There is a favorable outlook for leading Chinese medicine companies with advantages in formulas, raw materials, and brand recognition, as well as for consumer-oriented Chinese medicine that extends the industrial chain [2]

Market Overview - The A-share market opened lower but rebounded, with the Shanghai Composite Index up 0.21%, the Shenzhen Component Index up 0.72%, and the ChiNext Index up 0.71 [1] - Total market turnover reached 983.6 billion yuan, a decrease of 113.4 billion yuan compared to the previous day [1] - Over 3,500 stocks in the market experienced gains [1] Sector Performance - The lithium mining sector continued to rebound, while the consumer sectors in Fujian and Hainan remained active [1] - Semiconductor equipment and oil & gas stocks performed well, with the CPO concept recovering in the morning session [1] - The pharmaceutical and banking sectors experienced corrections, and AI application sectors remained sluggish [1] ETF Performance - The semiconductor equipment sector led the gains in ETFs, with several funds such as Huaxia Fund's Sci-Tech Semiconductor ETF and Haitai Baipin Fund's Sci-Tech Semiconductor Equipment ETF rising over 3% [1] - The rare metals sector also saw a rebound, with ICBC Credit Suisse's Rare Metals ETF and GF Fund's Rare Metals ETF increasing by 2% and 1.99%, respectively [1] - Oil & gas stocks showed strong performance, with the Yinhua Fund's Oil & Gas Resources ETF rising by 1.84% [1] - The traditional Chinese medicine sector lagged, with both the Chinese Medicine 50 ETF and the Chinese Medicine ETF declining by 1% [1] - The Hong Kong innovative drug sector fell, with the Hang Seng Medical ETF and the Hong Kong Innovative Drug 50 ETF both down by 1% [1]

Core Viewpoint - The Chinese medicine sector is experiencing a downturn, with institutional holdings at a record low, while certain ETFs are showing resilience amidst broader market declines [1][2]. Group 1: Market Performance - The A-share market indices collectively declined, with the Shanghai Composite Index down 0.97% to 3990 points, and a total market turnover of 1.98 trillion yuan, a decrease of 853 billion yuan from the previous trading day [1]. - Despite the overall market downturn, the Chinese medicine ETFs, including the Chinese Medicine ETF and the Chinese Medicine 50 ETF, saw an increase in value [1]. Group 2: Institutional Holdings and Financial Performance - As of Q3 2025, the proportion of Chinese medicine holdings in funds has dropped to 0.20%, the lowest since 2021, primarily due to performance pressures and capital being drawn to innovative drugs and "AI + healthcare" sectors [2]. - The overall revenue growth rate for the Chinese medicine sector in Q3 2025 was -1.57% year-on-year and -6.15% quarter-on-quarter, with net profit declining by 5.25% year-on-year and 29.32% quarter-on-quarter [2]. - The sales gross margin and net profit margin for the sector were reported at 40.40% and 9.21%, respectively, with the gross margin showing a year-on-year increase of 0.49 percentage points but a quarter-on-quarter decrease of 1.00 percentage points [2]. Group 3: Industry Outlook and Recommendations - The Chinese medicine sector is undergoing a transformation period, facing challenges from weak sales in both pharmacy and hospital channels, with OTC leading companies showing stronger performance resilience [3]. - The introduction of the fourth batch of centralized procurement for traditional Chinese medicine is expected to have a limited impact on listed companies, alleviating previous market concerns [3]. - There is potential for recovery in the OTC sector, particularly for companies with strong brand power and good inventory management, as flu incidence rates are rising [3]. - The industry is expected to see improved revenue growth following inventory clearance and a recovery in gross margins due to declining raw material prices [4].

Group 1 - The ETF market showed mixed performance on the 6th, with the Robot 50 ETF (159559) leading gains at 4.35% [2] - The E Fund Robot ETF (159530) also performed well, increasing by 4.34% [2] - The Military Industry ETF (512680) saw a rise of 3.56% [2] Group 2 - On the downside, the Traditional Chinese Medicine 50 ETF (562390) led losses, declining by 1.25% [2] - The Growth Enterprise Market Pharmaceutical ETF from Guotai (159377) fell by 1.2% [2] - The NASDAQ 100 ETF (513390) also experienced a drop of 1.2% [2]

Market Overview - A-shares indices collectively rose, with the Shanghai Composite Index reaching a new closing high for the year, up by 0.45% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.7341 trillion yuan, an increase of 138 billion yuan from the previous day [1] Sector Performance - The Robotics 50 ETF (159559) led the market gains, with the Robotics ETF E Fund (159530) rising over 4% [2] - Several military and robotics ETFs also saw gains exceeding 3% [2] - The Shanghai Municipal Government released a plan to develop the embodied intelligence industry, aiming for breakthroughs in at least 20 core algorithms and technologies by 2027, with a target industry scale exceeding 50 billion yuan [2] Investment Insights - Oriental Securities noted that AI investments and applications will accelerate the development of the robotics sector, with hardware companies likely to benefit from rapid advancements in AI [3] - The recent implementation of national collection results for traditional Chinese medicine in various provinces is expected to drive technological upgrades in the industry, favoring companies with comprehensive advantages and innovative capabilities [4] ETF Market Activity - The ETF market showed signs of cooling, with notable declines in traditional Chinese medicine-related ETFs [5] - The 5-Year Local Government Bond ETF (511060) had the highest turnover rate at 168.83% [6][7] - The Short-term Bond ETF (511360) led in trading volume, reaching 20 billion yuan [6] Upcoming Developments - New ETFs in the Hong Kong stock market related to the medical sector are set to launch, with a focus on the upcoming innovation drug industry conference [8] - The innovation drug sector is expected to maintain its growth trajectory, supported by policies and improving fundamentals [8]

Group 1 - The Chinese medicine concept stocks are experiencing a downward adjustment, with Zhaoli Pharmaceutical falling over 2%, and China Resources Sanjiu and Yiling Pharmaceutical both declining over 1% [1] - The ETF tracking the CSI Traditional Chinese Medicine Index has dropped over 1% due to market influences [1] Group 2 - The CSI Traditional Chinese Medicine Index selects listed companies involved in the production and sales of traditional Chinese medicine to reflect the overall performance of the sector [2] - Analysts indicate that the aging population and increased health awareness among residents are the main long-term drivers for consumer-oriented traditional Chinese medicine [2] - The traditional Chinese medicine industry is expected to showcase its long industrial chain and the characteristics of "prevention-treatment-nourishment," with a positive outlook for leading companies with advantages in formulas, raw materials, and brand recognition [2]

Group 1 - The Hong Kong innovative drug sector has recently cooled down after a significant rise, with the Hang Seng Biotechnology Index dropping by 2.51% and the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index down by 2.55% as of August 1 [1] - Multiple innovative drug stocks in Hong Kong experienced single-day declines exceeding 5%, while the traditional Chinese medicine sector rebounded with a 1.99% increase [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index had a year-to-date increase of 96.43%, with previous highs surpassing 100%, indicating a substantial prior gain in the sector [1] Group 2 - Concerns have been raised regarding the valuation bubble in the innovative drug sector, as many stocks, particularly in the A-share market, are considered to be at high valuations following the recent surge [2] - The market has begun to factor in early-stage clinical pipelines into valuations, which is risky due to the high failure rates associated with early-stage drug development [2] - The recent significant gains in the innovative drug sector, including a 90% increase in Hong Kong innovative drug ETFs, have led to profit-taking motives among investors [2] Group 3 - Long-term prospects for the innovative drug sector remain positive, but caution is advised due to the rapid short-term price increases and associated risks [3]

ETF Industry News - The three major indices experienced fluctuations and declines, with the Shanghai Composite Index down by 0.37%, the Shenzhen Component Index down by 0.17%, and the ChiNext Index down by 0.24%. However, several Traditional Chinese Medicine (TCM) sector ETFs saw gains, including the TCM 50 ETF (562390.SH) up by 2.36%, the TCM ETF (560080.SH) up by 1.89%, and the Huatai-PB TCM ETF (561510.SH) up by 1.75% [1] - The defense and military industry ETFs saw declines, with the Aerospace ETF (159227.SZ) down by 2.31%, the Defense ETF (512670.SH) down by 1.94%, and the Aerospace and Aviation ETF (159208.SZ) down by 1.85% [1] - According to a report from CITIC Securities, TCM companies have been increasing their R&D investments in recent years, and stable cash flow will support future R&D expenditures. The innovation in TCM is expected to contribute to steady growth, while innovative chemical and biological drugs may provide additional valuation flexibility [1] New ETF Launches - A batch of new ETFs is set to be launched, with six ETFs announcing their trading listings on July 29, followed by three more on July 30. The ETF market is expected to expand significantly, with over 10 ETFs currently in the issuance process [2] - The new ETFs cover a range of indices, including the CSI 500, ChiNext 50, and various thematic indices related to artificial intelligence and technology sectors [2] - Personal investors are increasingly prominent among the top holders of newly issued ETFs, with individual investors holding 93.57% of the shares in the Yifangda National General Aviation Industry ETF as of July 28. This trend indicates a high level of activity and consensus among personal investors, nearing the peak levels seen since the fourth quarter of last year [2][3] Market Performance Overview - On August 1, the three major indices collectively declined, with the Shanghai Composite Index closing at 3559.95 points, the Shenzhen Component Index at 10991.32 points, and the ChiNext Index at 2322.63 points. The highest intraday points were 3581.75, 11068.31, and 2348.02, respectively [4] - In terms of sector performance, the Environmental Protection, Media, and Light Industry sectors ranked highest with daily gains of 0.88%, 0.82%, and 0.65%, while the Oil and Petrochemical, Defense and Military, and Steel sectors ranked lowest with declines of 1.79%, 1.47%, and 1.26% [6] ETF Market Performance - The bond ETFs performed the best today, with an average daily change of 0.01%, while cross-border ETFs had the worst performance with an average daily change of -0.69% [9] - The top-performing ETFs today included the Photovoltaic ETF Leader (560980.SH) with a gain of 2.53%, the TCM 50 ETF (562390.SH) with a gain of 2.36%, and the Photovoltaic 50 ETF (159864.SZ) with a gain of 1.94% [11][12] - The trading volume for the top three stock ETFs was led by the A500 ETF Fund (512050.SH) with a trading volume of 4.183 billion, followed closely by the A500 ETF Southern (159352.SZ) with 4.166 billion, and the Sci-Tech 50 ETF (588000.SH) with 4.070 billion [14][15]